-
In the U.S., more than 1 out of 5 residents is fully vaccinated against COVID-19. But elsewhere in the world, vaccination rates are much lower. Some poor nations have yet to receive a single dose. -
Psychiatrists say their patients increasingly tell them that they're exhausted and unable to concentrate. Mental health experts say it's a normal reaction to abnormal times.
-
Many federally recognized tribes throughout the U.S. have had great success vaccinating their members against COVID-19. But those without federal recognition say they have a very different story. -
Health and Human Services Secretary Xavier Becerra is reversing restrictions on the use of fetal tissue in medical research implemented under former President Trump.
-
Coronavirus cases are surging in Michigan. NPR's Mary Louise Kelly talks with Dr. Joneigh Khaldun, Michigan's chief medical executive, about the state's decision not to implement new restrictions.
-
The U.S. Food and Drug Administration's decision to temporarily halt the use of the Johnson & Johnson COVID-19 vaccine is having ramifications globally.
-
Those with ties to the Amish are figuring out the best ways to educate and encourage them to get the shot, as COVID-19 cases surge in their communities.
-
Which communities could suffer most from the Johnson & Johnson vaccination pause? NPR's Ailsa Chang talks to Dr. Paul Adamson, an infectious diseases fellow at David Geffen School of Medicine at UCLA.
-
Many federally recognized tribes throughout the U.S. have had great success vaccinating their members against COVID-19. But those without federal recognition say they have a very different story.
-
No vaccine is 100% effective. Though so-called "breakthrough" COVID cases are rare, the virus is circulating widely. What's a vaccinated person to do? And ... not do?
-
Drugs that can help keep COVID-19 patients out of the hospital are playing only a small role in Michigan, where the pandemic is accelerating. Logistical challenges are to blame.
-
With a more contagious variant now dominant in the U.S., the country's genomic surveillance capacity is getting a major boost.
